Association of Azithromycin Use With Cardiovascular Mortality

Key Points Question Is use of azithromycin in an outpaitent setting associated with an increased short-term risk of cardiovascular death and sudden cardiac death in a diverse, community-based population? Findings In this cohort study including 7 824 681 antibiotic exposures, after propensity score adjustment, an outpatient prescription for azithromycin was associated with a significantly increased risk of cardiovascular death within 5 days of exposure compared with amoxicillin, an antibiotic not associated with adverse cardiovascular events. Meaning These findings suggest that prescribers should be aware of the potential association between azithromycin and cardiovascular death.

• Publication year

  2020

• Venue

  JAMA Network Open

• Publication date

  2020-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamanetworkopen.2020.8199PMID 32585019PMCID 7301226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities

  2018cited by this paper
• Use of azithromycin and risk of ventricular arrhythmia

  2017cited by this paper
• Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.

  2015cited by this paper
• Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.

  2014cited by this paper
• Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and Death

  2014cited by this paper
• Macrolide antibiotics and the risk of cardiac arrhythmias.

  2014cited by this paper
• Clinical practice. Community-acquired pneumonia.

  2014cited by this paper
• Cardiovascular risks with azithromycin and other antibacterial drugs.

  2013cited by this paper
• Use of azithromycin and death from cardiovascular causes.

  2013cited by this paper
• Azithromycin and the risk of cardiovascular death.

  2012cited by this paper
• Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data.

  2012cited by this paper
• ADHD drugs and serious cardiovascular events in children and young adults.

  2011cited by this paper
• Population trends in the incidence and outcomes of acute myocardial infarction.

  2010cited by this paper
• Adjustment for Multiple Cardiovascular Risk Factors Using a Summary Risk Score

  2008cited by this paper
• Oral erythromycin and the risk of sudden death.

  2005cited by this paper
• Sex and racial/ethnic disparities in outcomes after acute myocardial infarction: a cohort study among members of a large integrated health care delivery system in northern California.

  2005cited by this paper
• Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.

  2002cited by this paper
• QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

  2000cited by this paper
• Cardiac actions of erythromycin: influence of female sex.

  1998cited by this paper
• Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation.

  1997cited by this paper
• International classification of diseases: ninth revision.

  1978cited by this paper

• Continuous Maternal Care of Oral Diseases from Preconception to Lactation.

  2026cites this paper
• Underlying mechanisms of PPCPs on sleep disorders in the elderly: An integrated epidemiology and network toxicology study

  2025cites this paper
• Association of Oral Triptans and Other Oral Migraine Treatments With Cardiovascular Outcomes in Patients With a History of Cardiovascular Conditions

  2025cites this paper
• Trends in antibiotic use among cardiovascular heart disease inpatients at the Jakaya Kikwete Cardiac Institute in Tanzania from 2016 to 2022

  2025cites this paper
• Pediatric Ocular Rosacea: Clinical Features and Long-Term Maintenance Therapy with Topical Cyclosporine

  2025cites this paper
• Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health

  2025cites this paper
• Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study

  2025cites this paper
• Impact of Azithromycin on the Predisposition to Cardiac Arrhythmias in Adult Patients: A Systematic Review

  2024cites this paper
• The safety profile of Azithromycin in pediatrics: a pharmacovigilance disproportionality analysis.

  2024cites this paper
• Masqueraders Around Disaster: Clinical Features of Scrub Typhus in Fukushima, Japan

  2024cites this paper
• An Overview of the Impact of Bacterial Infections and the Associated Mortality Predictors in Patients with COVID-19 Admitted to a Tertiary Center from Eastern Europe

  2023cites this paper
• Relationship Between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease

  2023cites this paper
• Clinical Effectiveness and Outcomes of Azithromycin versus Doxycycline Containing Regimen in Inpatients with Community Acquired Pneumonia: A Retrospective Cohort Study

  2023cites this paper
• A single dose of ciprofloxacin reduces the duration of diarrhea among service members deployed in Africa.

  2023cites this paper
• The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin–clavulanate in US Veterans

  2022cites this paper
• Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis

  2022cites this paper
• Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections

  2022cites this paper
• Effects of azithromycin on ventricular repolarization in children with COVID-19

  2022cites this paper
• Women: Diet, Cardiometabolic Health, and Functional Medicine.

  2022cites this paper
• Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure.

  2022cites this paper
• Practices, knowledge, and attitudes of community pharmacists towards dispensing drugs during the COVID-19 pandemic: A cross sectional study from Jordan

  2022cites this paper
• Evaluation of Effect of Azithromycin on The Heart of Adult Male Albino Rats and The Possible Protective role of VIT.C (Histological and Immune-histochemical Study)

  2022cites this paper
• Treatment outcomes of oral doxycycline versus intravenous azithromycin in adults hospitalized with scrub typhus: A retrospective study using inverse probability treatment weighting (IPTW) propensity analysis.

  2022cites this paper
• Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro

  2021cites this paper
• Ocular manifestations of rosacea: A clinical review

  2021cites this paper
• Enteral and Parenteral Antimicrobials Used in the SDD Policy

  2021cites this paper
• Community pharmacist use of mobile ECG to inform drug therapy decision making for patients receiving QTc prolonging medications

  2021cites this paper
• Quality, efficacy, safety—it is not enough!

  2021cites this paper
• Antibiotics for secondary prevention of coronary heart disease.

  2021cites this paper
• Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go

  2021cites this paper
• Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study

  2021cites this paper
• Extrinsic and Intrinsic Responses in the Development and Progression of Atherosclerosis.

  2021cites this paper
• Azithromycin Associated with Increased Risk of Death in Outpatients.

  2020cites this paper
• Error in Results Section

  2020cites this paper
• Trends in U.S. outpatient antibiotic prescriptions during the COVID-19 pandemic

  2020cites this paper
• Searching for COVID-19 treatments: First, do no harm

  2020cites this paper
• Macrolides for patients with COVID-19 and concurrent pertussis infection

  2020cites this paper
• Azithromycin in patients with COVID-19: Friend or foe?

  2020cites this paper
• Azithromycin in the treatment of COVID-19: a review

  2020cites this paper